Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merus Labs completes $Cdn10mm private placement

Executive Summary

Canadian spec pharma Merus Labs International Inc. sold 10k Series A convertible preferred shares for $1k to a Canadian institutional investor, grossing $Cdn10mm ($9.2mm). The shares, which expire at the end of October 2019, convert into common stock at $Cdn2.20 apiece. The investor may redeem the stock only if Merus does not complete a product acquisition by the end of the year.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Other

Related Companies